一种消化系统恶性肿瘤标志物及其制备抑制消化系统恶性肿瘤药物的方法
The invention belongs to the biopharmaceutical field, and particularly relates to a digestive system malignant tumor marker, and a method for preparing drugs for restraining digestive system malignanttumors. HYAL2 is used for clinical diagnosis of the digestive system malignant tumors, luminescence quantification PCR is used for detecting the expression situation in the digestive system malignanttumors, and according to the expression situation, HYAL2 is used as a molecule maker for the early diagnosis of the digestive system malignant tumors. A carrier for interference HYAL2 gene expressionis constructed for the drugs for restraining the digestive system malignant tumors. The constructed carrier is used for preparing the drugs for in vitro application or in vivo application. Massive experiment data proves that the HYAL2 exerts important adjusting and controlling effects in the generation and development process of the digestive system malignant tumors, the interference HYAL2 gene expression can notably restrain the proliferation and the migration of digestive system malignant tumor cells, and the HYAL2 is hopeful to prepare a new drug for preventing and treating the digestive system malignant tumors..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 26. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2021-02-26, Last updated: 2021-03-11 |
|---|
| Patentnummer: |
CN110042160 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA004285247 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA004285247 | ||
| 003 | DE-627 | ||
| 005 | 20230503195352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210529s2021 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)EPA004285247 | ||
| 035 | |a (EPA)CN110042160 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 245 | 1 | 0 | |a 一种消化系统恶性肿瘤标志物及其制备抑制消化系统恶性肿瘤药物的方法 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2021-02-26, Last updated: 2021-03-11 | ||
| 520 | |a The invention belongs to the biopharmaceutical field, and particularly relates to a digestive system malignant tumor marker, and a method for preparing drugs for restraining digestive system malignanttumors. HYAL2 is used for clinical diagnosis of the digestive system malignant tumors, luminescence quantification PCR is used for detecting the expression situation in the digestive system malignanttumors, and according to the expression situation, HYAL2 is used as a molecule maker for the early diagnosis of the digestive system malignant tumors. A carrier for interference HYAL2 gene expressionis constructed for the drugs for restraining the digestive system malignant tumors. The constructed carrier is used for preparing the drugs for in vitro application or in vivo application. Massive experiment data proves that the HYAL2 exerts important adjusting and controlling effects in the generation and development process of the digestive system malignant tumors, the interference HYAL2 gene expression can notably restrain the proliferation and the migration of digestive system malignant tumor cells, and the HYAL2 is hopeful to prepare a new drug for preventing and treating the digestive system malignant tumors. | ||
| 650 | 4 | |a C12Q | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K | |
| 650 | 4 | |a C12N | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61P | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 26. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:26 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=CN110042160B |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 26 |c 02 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 26 |c 02 | ||